CD8A and neoplasm: CD8-positive (CD8+) T cells infiltrating the tumor microenvironment (TME) are considered the key tumor killing cells and main target of the PD-1/L1 axis and have thus been proposed to be predictive of the clinical efficacy of immunotherapy [3, 4].